Intellectia LogoIntellectia
Product
Resources
Markets
Pricing
Sign inTry for Free
Intellectia Logo
Sign in
Intellectia Logo

Product

Features
Financial AI Agent
Stock Technical Analysis
Stock Monitor
Hedge Fund Tracker
Crypto Technical Analysis
AI Screener
Trading Strategies
AI Stock Picker
Swing Trading
Earnings Trading
Stock Chart Patterns
Daytrading Center

Resources

Learn
Blog
Earnings
Tutorial
Help Center
Company
About Us
Contact
Press
Reward Program
Partner Program
Dividend Calculator
Dividend Yield Calculator
Options Profit Calculator
Compare
TradingView
SeekingAlpha

Markets

Trending Stocks
Hot Crypto
Trending News
All Stocks
Pricing
Start for Free
  1. Home
    2. >
  2. Stock
    3. >
  3. MDT
stocks logo

MDT

-
Add to WatchlistAdvanced Chart
$
0.000
0.000(0.000%)
High
--
Open
--
VWAP
--
Vol
--
Mkt Cap
--
Low
--
Amount
--
EV/EBITDA(TTM)
--
Total Shares
--
EV
--
EV/OCF(TTM)
--
P/S(TTM)
--

Market Estimates

Earnings Estimates
Earnings Estimates
Revenue
YoY Chg
EPS
YoYChg
FY2025Q4
FY2026Q1
FY2026Q2
8.81B
+2.63%
1.577
+8.01%
8.33B
+5.27%
1.324
+7.67%
8.75B
+4.12%
1.408
+11.78%
Estimates Revision
The market is revising Downward the revenue expectations for Medtronic plc (MDT) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 0.92%.
Revenue Estimates for FY2025
Revise Downward
down Image
-0.23%
In Past 3 Month
EPS Estimates for FY2025
Revise Downward
down Image
-0.12%
In Past 3 Month
Stock Price
Go Up
up Image
+0.92%
In Past 3 Month
19 Analyst Rating
up Image0
Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 96.00 USD with a low forecast of 85.00 USD and a high forecast of 109.00  USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
9 Buy
9 Hold
1 Sell
Moderate Buy
up Image0
Current: 86.180
sliders
Low
85.00
Averages
96.00
High
109.00
up Image0
Current: 86.180
sliders
Low
85.00
Averages
96.00
High
109.00
Truist Securities
Richard Newitter
Hold
Maintains
$93 → $90
2025-04-11
Reason
Truist Securities
Richard Newitter
Price Target
$93 → $90
2025-04-11
Maintains
Hold
Reason
Truist lowered the firm's price target on Medtronic to $90 from $93 and keeps a Hold rating on the shares as part of a broad research note previewing Q1 results in Medical Technology. The group's revenue and earnings are less at risk than it could be for a number of other sub-sectors, which will likely keep investors relatively interested in the space even with some tariff choppiness in the backdrop, though the firm is also bracing for cautious 2025 outlooks as companies and models will likely begin to dial-in some macro uncertainty, the analyst tells investors in a research note.
Citigroup
Joanne Wuensch
Hold
to
Strong Buy
Upgrades
$92 → $107
2025-03-04
Reason
Citigroup
Joanne Wuensch
Price Target
$92 → $107
2025-03-04
Upgrades
Hold
to
Strong Buy
Reason
Needham
Mike Matson
Hold
Reiterates
n/a
2025-02-19
Reason
Needham
Mike Matson
Price Target
n/a
2025-02-19
Reiterates
Hold
Reason
Baird
David Rescott
Hold
Maintains
$90 → $91
2025-02-19
Reason
Baird
David Rescott
Price Target
$90 → $91
2025-02-19
Maintains
Hold
Reason
Baird analyst David Rescott raised the firm's price target on Medtronic to $91 from $90 and keeps a Neutral rating on the shares. The firm updated its model following Q4 results and said the MedSurg miss clouds an improving return to stability.
UBS
Danielle Antalffy
Hold
Maintains
$85 → $95
2025-02-19
Reason
UBS
Danielle Antalffy
Price Target
$85 → $95
2025-02-19
Maintains
Hold
Reason
RBC Capital
Shagun Singh
Buy
Reiterates
$105
2025-02-19
Reason
RBC Capital
Shagun Singh
Price Target
$105
2025-02-19
Reiterates
Buy
Reason
See All Ratings

Valuation Metrics

The current forward P/E ratio for Medtronic PLC (MDT.N) is 14.96, compared to its 5-year average forward P/E of 17.77. For a more detailed relative valuation and DCF analysis to assess Medtronic PLC 's fair value, click here.
    Forward PE
    Forward EV/EBITDA
    Forward PS

Forward PE

The forward P/E ratio is a valuation metric that divides a company's current stock price by its estimated future earnings per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Fair
5Y Average PE
17.77
Current PE
14.96
Overvalued PE
20.73
Undervalued PE
14.81

Forward EV/EBITDA

The forward EV/EBITDA ratio is a valuation metric that divides a company's enterprise value (EV) by its estimated future earnings before interest, taxes, depreciation, and amortization (EBITDA) over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average EV/EBITDA
14.93
Current EV/EBITDA
12.63
Overvalued EV/EBITDA
17.00
Undervalued EV/EBITDA
12.86

Forward PS

The forward P/S ratio is a valuation metric that divides a company's current stock price by its estimated future sales (or revenue) per share over the next 12 months.
StronglyUndervaluedUndervaluedFairOvervaluedStronglyOvervalueddotted line Image
Undervalued
5Y Average PS
3.94
Current PS
3.12
Overvalued PS
4.68
Undervalued PS
3.20

Financials

Annual
Quarterly
N/A
Total Revenue
N/A
Operating Profit
N/A
Net Income after Tax
N/A
EPS - Diluted
N/A
Free Cash Flow
N/A
Gross Profit Margin - %
N/A
FCF Margin - %
N/A
Net Margin - %
N/A
ROIC

Trading Trends

    Insider
    Hedge Fund
    Congress Trading
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Hedge Fund
Hedge Funds areBuying! The buying amount has increased 2583.26% over the last quarter.
Sold
Bought
Congress Trading
Congress are Neutral. There are no significant trading trends over the last month.
Sold
Bought
Insider
Insiders are Neutral. There are no significant trading trends over the last month.
Sold
Bought

MDT News & Events

Events Timeline

(ET)
2025-04-27
17:44:02
Medtronic announces outcomes from two studies in AFib patients
select
2025-04-27
17:41:18
Medtronic announces Expand URO IDE study met primary safety, effective endpoint
select
2025-04-25 (ET)
2025-04-25
17:46:10
Medtronic receives FDA approval for OmniaSecure defibrillation lead
select
Sign Up For More Events
Sign Up For More Events

News

Preview
3.5
05-16WSJ
The Next Frontier to Treat Cancer: Electricity

  • Electricity as a Treatment: Electricity is being explored as a potential treatment for various diseases, including rheumatoid arthritis and challenging cancers like glioblastoma and pancreatic cancer.

  • Advancements in Medical Technology: New technologies are expanding the use of electric fields and pulses in medicine, building on established treatments like pacemakers and electroconvulsive therapy.

Preview
9.5
05-16NASDAQ.COM
Century Therapeutics, Inc. (IPSC) Q1 Earnings and Revenues Top Estimates

  • Earnings Performance: Century Therapeutics, Inc. reported quarterly earnings of $0.89 per share, significantly surpassing the Zacks Consensus Estimate of a loss of $0.31, marking an earnings surprise of 387.10%. The company also achieved revenues of $109.16 million, exceeding estimates by 139.84%.

  • Future Outlook: Despite a 51.6% decline in shares this year, Century Therapeutics holds a Zacks Rank #2 (Buy), indicating potential for future outperformance based on favorable earnings estimate revisions and industry ranking within the top 26% of Zacks industries.

Preview
2.0
05-15NASDAQ.COM
ISRG Stock Gains More than 8% YTD: Will the Uptrend Continue?

  • Stock Performance and Financials: Intuitive Surgical's shares have risen 9.7% in the past month after a significant decline, driven by strong revenue growth of 19.2% year-over-year to $2.25 billion in Q1 2025, despite ongoing tariff risks and competition in the robotic-assisted surgery market.

  • Strategic Initiatives and Challenges: The company is focusing on technological advancements, international expansion, and manufacturing improvements while facing challenges from global trade tensions and increased competition from major players like Johnson & Johnson and Medtronic.

Sign Up For More News

People Also Watch

FAQ

arrow icon

What is Medtronic PLC (MDT) stock price today?

The current price of MDT is 86.18 USD — it has increased 0.08 % in the last trading day.

arrow icon

What is Medtronic PLC (MDT)'s business?

Medtronic Public Limited Company is an Ireland-based company, which provides healthcare technology solutions. The Company’s products category includes Advanced Surgical Technology; Cardiac Rhythm; Cardiovascular; Digestive & Gastrointestinal; Ear, Nose & Throat; General Surgery; Gynecological; Neurological; Oral & Maxillofacial; Patient Monitoring; Renal Care; Respiratory; Spinal & Orthopedic; Surgical Navigation & Imaging; Urological; Product Manuals; Product Ordering & Inquiries; and Product Performance & Advisories. Its products include Cardiac Implantable Electronic Device (CIED) Stabilization, Aortic Stent Graft Products, CareLink Personal Therapy Management Software, CareLink Pro Therapy Management Software. Its services and solutions include Ambulatory Surgery Center Resources, Care Management Services, Digital Connectivity Information Technology (IT) Support, Equipment Services and Support, Innovation Lab, Medtronic Healthcare Consulting, and Office-Based Sinus Surgery.

arrow icon

What is the price predicton of MDT Stock?

Wall Street analysts forecast MDT stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for MDT is 96.00 USD with a low forecast of 85.00 USD and a high forecast of 109.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.

arrow icon

What is Medtronic PLC (MDT)'s revenue for the last quarter?

Medtronic PLC revenue for the last quarter amounts to 8.29B USD, increased 2.51 % YoY.

arrow icon

What is Medtronic PLC (MDT)'s earnings per share (EPS) for the last quarter?

Medtronic PLC. EPS for the last quarter amounts to 1.01 USD, increased 2.02 % YoY.

arrow icon

What changes have occurred in the market's expectations for Medtronic PLC (MDT)'s fundamentals?

The market is revising Downward the revenue expectations for Medtronic plc (MDT) for FY2025, with the revenue forecasts being adjusted by -0.23% over the past three months. During the same period, the stock price has changed by 0.92%.
arrow icon

How many employees does Medtronic PLC (MDT). have?

Medtronic PLC (MDT) has 95000 emplpoyees as of May 17 2025.

arrow icon

What is Medtronic PLC (MDT) market cap?

Today MDT has the market capitalization of 110.44B USD.

Intellectia LogoIntellectiaIntellectia LogoIntellectia

Redefine Your Investment Decisions

TwitterTwitterYoutubeYoutubeQuoraQuoraDiscordDiscordLinkedinLinkedinTelegramTelegram

Copyright © 2025 Intellectia.AI. All Rights Reserved.

pci certified logo
Company
HomeContactAbout UsNews Release
Compare
TradingViewSeeking Alpha
Features
Financial AI AgentStock Technical AnalysisStock MonitorHedge Fund TrackerCrypto Technical AnalysisAI ScreenerDaytrading Center
Strategies
AI Stock PickerSwing TradingStock Chart PatternsEarnings Trading
Free Tools
Dividend CalculatorDividend Yield CalculatorOptions Profit Calculator
Resource
BlogTutorialEarningsTrending StocksCrypto MarketPartner ProgramTerms of UsePrivacy PolicySitemap
Start for Free